Lifeward (LFWD) said Thursday the US Food and Drug Administration has cleared ReWalk 7, the newest version of its personal exoskeleton device.
According to Lifeward, ReWalk 7 is a wearable device that allows users with spinal cord injury to stand and walk. The company said sales of ReWalk 7 in the US will start "as soon as the product is available."
Lifeward shares climbed by more than 70% in early trading on Thursday.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。